Real-World Treatment Patterns and Outcomes Among Multiple Myeloma Patients with Asthma and COPD in the United States

Rice, Megan S.; Naeger, Sarah; Singh, Erin

doi:10.1007/s40487-021-00146-4

Cited by 7 publications

(5 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A large Portuguese study has shown the odds of in-hospital mortality are lower in depressed patients, but the length of hospital stay is longer [37]. Similarly, in real-world data, overall survival from chronic obstructive pulmonary disease (COPD) in multiple myeloma is worse, which contradicts our finding of a low odds ratio of mortality in hospitalized patients [38,39]. The reason for these findings remains unclear.…”

Section: Predictors Of Aprdrg Disabilitycontrasting

confidence: 84%

Disparities in Outcomes of Hospitalizations Due to Multiple Myeloma: A Nationwide Comparison

Khadka,

Balaji,

Kaur

et al. 2023

Cureus

View full text Add to dashboard Cite

BackgroundWith the advent of novel treatments, there is a declining trend in the multiple myeloma (MM) mortality rate with an increasing hospitalization rate. However, there is limited population-based data on trends and outcomes of hospitalizations due to MM in the United States (US). MethodsWe analyzed the publicly available Nationwide Inpatient Sample (NIS) from 2007 to 2017 to identify MM hospitalizations. Results

show abstract

Section: Predictors Of Aprdrg Disabilitycontrasting

confidence: 84%

Disparities in Outcomes of Hospitalizations Due to Multiple Myeloma: A Nationwide Comparison

Khadka,

Balaji,

Kaur

et al. 2023

Cureus

View full text Add to dashboard Cite

show abstract

“…Similarly, patients with MM presented with asthma or COPD showed significantly longer time from first- to second-line treatment. Additionally, the OS from first-line therapy was remarkably lower among patients with COPD, with a statistically significant decline in the OS from second-line therapy [ 32 ]. As no previous studies in the Middle East and North Africa region have provided the effect of first- or second-line treatment on patients with associated asthma or COPD, this study will assess the OS and PFS in those patients and compare the influence of first- or second-line therapy on survival.…”

Section: Discussionmentioning

confidence: 99%

Real-World Registry on the Pharmacotherapy of Multiple Myeloma and Associated Renal and Pulmonary Impairments in the Greater Gulf Region: Protocol for a Retrospective Real-World Data Study

Nourallah,

Alshehri,

Alhejazi

et al. 2024

JMIR Res Protoc

View full text Add to dashboard Cite

Background Multiple myeloma (MM) is the second-most common cancer among hematological malignancies. Patients with active disease may experience several comorbidities, including renal insufficiency and asthma, which may lead to treatment failure. The treatment of relapsed or refractory MM (RRMM) has been associated with multiple factors, causing a decline in progression-free survival as well as overall survival with subsequent lines of therapy. Data about the characteristics of this group of patients in the Greater Gulf region are lacking. Objective The primary objective of this study is to describe the disease characteristics and various treatment approaches or regimens used in the management of patients with RRMM in the Greater Gulf region. Methods We will conduct a regional, retrospective study collecting real-world and epidemiological data on patients with MM in countries of the Greater Gulf region. Medical records will be used to obtain the required data. Around 150 to 170 patients’ records are planned to be retrospectively reviewed over 6 months without any cross-sectional or prospective intervention. Cases will be collected from Saudi Arabia, the United Arab Emirates, Kuwait, Oman, and Qatar. Descriptive as well as analytical statistics will be performed on the extracted data. The calculated sample size will allow us to estimate the percentages of RRMM cases with acceptable precision while complying with the challenges in light of data scarcity. We will obtain a comprehensive description of the demographic profile of patients with MM; treatment outcomes; the proportion of patients with MM with renal impairment and asthma, chronic obstructive pulmonary disease, or both at the time of diagnosis and any subsequent point; and data related to treatment lines, regimens, and MM-associated morbidities. Results Patient medical records were reviewed between June 2022 and January 2023 for eligibility and data extraction. A total of 148 patients were eligible for study inclusion, of whom 64.2% (n=95) were male and 35.8% (n=53) were female. The study is currently in its final stages of data analysis. The final manuscript is expected to be published in 2024. Conclusions Although MM is a predominant hematological disease, data on its prevalence and patients’ characteristics in the Greater Gulf region are scarce. Therefore, this study will give us real-world insights into disease characteristics and various management approaches of patients with MM in the Greater Gulf region. International Registered Report Identifier (IRRID) DERR1-10.2196/49861

show abstract

“…And statistical analysis of clinical indicators showed that there was a significant difference in the expression of renal injury compared with the adverse prognosis of MM. The prognosis of MM patients is affected by many factors, such as international staging system, cytogenetic abnormality, underlying disease and age [ 32 ], studies have shown that IFI16 can be used as a biomarker for poor prognosis in MM [ 33 ]. Later, we will further follow up and monitor the survival and prognosis of MM patients.…”

Section: Discussionmentioning

confidence: 99%

Serum hsa_circ_0087776 as a new oncologic marker for the joint diagnosis of multiple myeloma

et al. 2021

View full text Add to dashboard Cite

Multiple myeloma (MM) is a hematologic malignancy caused by abnormal proliferation of bone marrow plasma cells, which lacks diagnostic markers and has a general prognosis. At present, the understanding of its pathogenesis provides the basis for the combined diagnosis and new targeted therapy of the disease. In this study, quantitative real-time PCR was used to detect 136 MM patients and 74 healthy controls, and the clinical application value of hsa_circ_0087776 as a new tumor marker and combined diagnosis was evaluated. The results showed that the expression of hsa_circ_0087776 was significantly lower in serum of MM patients ( P -value < 0.0001), and the expression was consistent in MM cells. In the analysis of clinicopathological parameters, it was found that there were significant statistical differences with MM stage and renal injury. In addition, it significantly increased the sensitivity with ALB, β₂-MG joint diagnosis, to provide a basis for diagnosis, improve the prognosis of the disease, improve the survival of patients and quality of life. These studies suggest that hsa_circ_0087776 can be used as a new oncology marker for the combined diagnosis of MM. Impact statement: Various evidences have shown that the role of circRNA in the occurrence and development of diseases is potentially unknown and untapped. Therefore, it has a broad prospect to find circRNA specifically expressed in MM patients for combined diagnosis and targeted therapy of MM. However, MM lacks such specific tumor markers. Therefore, the discovery of new specific tumor markers for combined diagnosis is an important milestone in the development of medical history. In the research, we founded hsa_circ_0087776 can be used as a new oncology marker for combined diagnosis of MM.

show abstract

Real-World Treatment Patterns and Outcomes Among Multiple Myeloma Patients with Asthma and COPD in the United States

Cited by 7 publications

References 17 publications

Disparities in Outcomes of Hospitalizations Due to Multiple Myeloma: A Nationwide Comparison

Disparities in Outcomes of Hospitalizations Due to Multiple Myeloma: A Nationwide Comparison

Real-World Registry on the Pharmacotherapy of Multiple Myeloma and Associated Renal and Pulmonary Impairments in the Greater Gulf Region: Protocol for a Retrospective Real-World Data Study

Serum hsa_circ_0087776 as a new oncologic marker for the joint diagnosis of multiple myeloma

Contact Info

Product

Resources

About